Search Results - "MEISSNER, H CODY"

Refine Results
  1. 1

    Viral Bronchiolitis in Children by Meissner, H. Cody

    Published in The New England journal of medicine (07-01-2016)
    “…This review on bronchiolitis in young children considers the viruses involved, the current understanding of pathogenesis, host genetic factors and the…”
    Get full text
    Journal Article
  2. 2

    Understanding Vaccine Safety and the Roles of the FDA and the CDC by Meissner, H. Cody

    Published in The New England journal of medicine (28-04-2022)
    “…Development and public acceptance of vaccines are crucial for disease control. This review covers the process of evaluating vaccines for safety and efficacy,…”
    Get full text
    Journal Article
  3. 3

    Approaching the End of the Era of Uncontrolled Respiratory Syncytial Virus Disease by Cody Meissner, H

    Published in The Journal of infectious diseases (03-03-2021)
    “…Much of the world’s attention is focused on disease caused by a novel coronavirus. But in the shadow of the severe acute respiratory syndrome coronavirus 2…”
    Get full text
    Journal Article
  4. 4
  5. 5

    Anticipating the Next Pandemic by Meissner, H. Cody, Kapogiannis, Bill G., Wolfe, Daniel N.

    Published in The New England journal of medicine (18-07-2024)
    “…Project NextGen plans to support trials assessing the safety, efficacy, and immunogenicity of experimental Covid-19 vaccines. New platforms could also enable a…”
    Get full text
    Journal Article
  6. 6

    Varicella Prevention in the United States: A Review of Successes and Challenges by Marin, Mona, Meissner, H. Cody, Seward, Jane F

    Published in Pediatrics (Evanston) (01-09-2008)
    “…In 1995, the United States was the first country to introduce a universal 1-dose childhood varicella vaccination program. In 2006, the US varicella vaccine…”
    Get full text
    Journal Article
  7. 7
  8. 8
  9. 9

    Utilization of chronic lung disease treatment before the respiratory syncytial virus season as palivizumab prophylaxis qualifier in the American Academy of Pediatrics Guidelines by Choi, Yoonyoung, Meissner, H. Cody, Hampp, Christian, Park, Haesuk, Winterstein, Almut G.

    Published in European journal of pediatrics (01-02-2022)
    “…Guidelines from the American Academy of Pediatrics recommend palivizumab immunoprophylaxis for children with CLD in their second year of life if they continue…”
    Get full text
    Journal Article
  10. 10

    Understanding FDA-Approved Labeling and CDC Recommendations for Use of Vaccines by Meissner, H Cody, Farizo, Karen, Pratt, Douglas, Pickering, Larry K, Cohn, Amanda C

    Published in Pediatrics (Evanston) (01-09-2018)
    “…Adherence to recommendations for the use of licensed vaccines ensures maximum individual and societal benefits from the national immunization program. The US…”
    Get full text
    Journal Article
  11. 11

    Patient equity and respiratory syncytial virus Immunoprophylaxis by Cody Meissner, H

    Published in Israel journal of health policy research (28-01-2019)
    “…An analysis of benefit and cost is critical for independent advisory groups that provide evidence-based recommendations. In many countries, the role of RSV…”
    Get full text
    Journal Article
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17

    Disarming the Respiratory Syncytial Virus by Meissner, H. Cody

    Published in The New England journal of medicine (30-07-2020)
    “…Respiratory syncytial virus (RSV) causes predictable, annual outbreaks of respiratory tract disease in temperate as well as tropical climates around the globe…”
    Get full text
    Journal Article
  18. 18

    Complexity in Assessing the Benefit vs Risk of Vaccines: Experience With Rotavirus and Dengue Virus Vaccines by Meissner, H. Cody

    “…This Viewpoint uses experience with rotavirus vaccine–induced intussusception and dengue virus vaccine–induced shock syndrome to discuss issues of disease…”
    Get full text
    Journal Article
  19. 19
  20. 20

    Revised Indications for the Use of Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous for the Prevention of Respiratory Syncytial Virus Infections by Meissner, H. Cody, Long, Sarah S, Committee on Infectious Diseases, and Committee on Fetus and Newborn

    Published in Pediatrics (Evanston) (01-12-2003)
    “…Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous (RSV-IGIV) are licensed by the Food and Drug Administration for use in preventing…”
    Get full text
    Journal Article